Progesterone Receptor Negative Not Yet Recruiting Phase 1 Trials for Talazoparib (DB11760)

IndicationStatusPhase
DBCOND0038639 (Progesterone Receptor Negative)Not Yet Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02567396Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney DysfunctionTreatment